Literature DB >> 21913135

Predictive value of baseline neutrophil/lymphocyte ratio for T4 disease in wall-penetrating gastric cancer.

Masaki Aizawa1, Naoto Gotohda, Shinichiro Takahashi, Masaru Konishi, Taira Kinoshita.   

Abstract

BACKGROUND: Multimodality therapy has been used in the management of gastric cancer associated with locoregional spread. However, the accurate clinical staging still remains to be established. The neutrophil/lymphocyte ratio (NLR) in the peripheral blood is reported to be an easily assessable prognostic factor in cancer patients. We evaluated the predictive significance of the NLR and other serological parameters in patients with wall-penetrating gastric cancer.
METHODS: Two hundred sixty-two patients who underwent gastric cancer surgery between 2002 and 2005 were identified retrospectively. Wall penetration was defined as wall invasion deeper than the muscularis propria (≥ T2). Blood data were collected from routinely performed blood examinations before treatment and were analyzed with respect to T stage, nodal status, and histological features. A high NLR was defined as less than 3.2 based on ROC curve analysis, and the predictive value of a high NLR for T4 cancer was evaluated.
RESULTS: Elevated levels of NLR (P = 0.004) and C-reactive protein (CRP) (P = 0.017) and the decrease in lymphocyte count (Lym, P = 0.032) and serum hemoglobin (Hb, P < 0.001) were correlated with the T stage, but there was no meaningful correlation with either positive nodal status or histological differentiation. With respect to the predictive value for stage T4, an elevated NLR (OR = 2.206, 95% CI = 1.187-4.100; P = 0.012), decrease of Hb (OR = 1.875, 95% CI = 1.005-3.500; P = 0.048), and poorly differentiated histology (OR = 3.134, 95% CI = 1.593-6.167; P = 0.001) were identified as independent predictive factors.
CONCLUSION: Our findings suggest that the preoperative values of the NLR may be reliable for predicting T4 disease.

Entities:  

Mesh:

Year:  2011        PMID: 21913135     DOI: 10.1007/s00268-011-1269-2

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  29 in total

1.  Gastric cancer: preoperative local staging with 3D multi-detector row CT--correlation with surgical and histopathologic results.

Authors:  Chiao-Yun Chen; Jui-Sheng Hsu; Deng-Chyang Wu; Wan-Yi Kang; Jan-Sing Hsieh; Twei-Shiun Jaw; Ming-Tsang Wu; Gin-Chung Liu
Journal:  Radiology       Date:  2007-02       Impact factor: 11.105

2.  Prognostic significance of host- and tumor-related factors in patients with gastric cancer.

Authors:  Yasuhiko Mohri; Kouji Tanaka; Masaki Ohi; Takeshi Yokoe; Chikao Miki; Masato Kusunoki
Journal:  World J Surg       Date:  2010-02       Impact factor: 3.352

3.  Preoperative staging of gastric cancer by endoscopic ultrasonography and multidetector-row computed tomography.

Authors:  Sung Wook Hwang; Dong Ho Lee; Sang Hyub Lee; Young Soo Park; Jin Hyeok Hwang; Jin Wook Kim; Sook Hyang Jung; Na Young Kim; Young Hoon Kim; Kyoung Ho Lee; Hyung-Ho Kim; Do Joong Park; Hye Seung Lee; Hyun Chae Jung; In Sung Song
Journal:  J Gastroenterol Hepatol       Date:  2010-03       Impact factor: 4.029

4.  Is gastric carcinoma different between Japan and the United States?

Authors:  Y Noguchi; T Yoshikawa; A Tsuburaya; H Motohashi; M S Karpeh; M F Brennan
Journal:  Cancer       Date:  2000-12-01       Impact factor: 6.860

5.  Interleukin 8 and vascular endothelial growth factor -- prognostic factors in human gastric carcinomas?

Authors:  S Kido; Y Kitadai; N Hattori; K Haruma; T Kido; M Ohta; S Tanaka; M Yoshihara; K Sumii; Y Ohmoto; K Chayama
Journal:  Eur J Cancer       Date:  2001-08       Impact factor: 9.162

Review 6.  Inflammation and cancer.

Authors:  Lisa M Coussens; Zena Werb
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

7.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

8.  Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG-ps) in patients receiving palliative chemotherapy for gastroesophageal cancer.

Authors:  Andrew B C Crumley; Robert C Stuart; Margaret McKernan; Alexander C McDonald; Donald C McMillan
Journal:  J Gastroenterol Hepatol       Date:  2007-07-20       Impact factor: 4.029

9.  Significance of increased neutrophils in patients with advanced colorectal cancer.

Authors:  A Satomi; S Murakami; K Ishida; M Mastuki; T Hashimoto; M Sonoda
Journal:  Acta Oncol       Date:  1995       Impact factor: 4.089

10.  Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas.

Authors:  Isabelle Ray-Coquard; Claire Cropet; Martine Van Glabbeke; Catherine Sebban; Axel Le Cesne; Ian Judson; Olivier Tredan; Jaap Verweij; Pierre Biron; Inthidar Labidi; Jean-Paul Guastalla; Thomas Bachelot; David Perol; Sylvie Chabaud; Pancras C W Hogendoorn; Philippe Cassier; Armelle Dufresne; Jean-Yves Blay
Journal:  Cancer Res       Date:  2009-06-23       Impact factor: 12.701

View more
  20 in total

1.  Usefulness of the neutrophil/lymphocyte ratio measured preoperatively as a predictor of peritoneal metastasis in patients with advanced gastric cancer.

Authors:  Yusuke Nakayama; Naoto Gotohda; Hidehito Shibasaki; Shogo Nomura; Takahiro Kinoshita; Ryuichi Hayashi
Journal:  Surg Today       Date:  2014-05-16       Impact factor: 2.549

2.  Surgery for Locally Advanced GIT Cancers Has Potentially Good Postoperative Outcomes in a Tertiary Hospital.

Authors:  Anwar Tawfik Amin; Ahmed A S Salem; Abeer Ibrahim
Journal:  J Gastrointest Cancer       Date:  2020-03

3.  Predictive Value of the Neutrophil/Lymphocyte Ratio in Peritoneal and/or Metastatic Disease at Staging Laparoscopy for Gastric and Esophageal Adenocarcinoma.

Authors:  Tal Grenader; Yevgeni Plotkin; Borzoueh Mohammadi; Khaled Dawas; Majid Hashemi; Muntzer Mughal; John A Bridgewater
Journal:  J Gastrointest Cancer       Date:  2015-09

4.  Pretreatment Neutrophil to Lymphocyte Ratio Independently Predicts Disease-specific Survival in Resectable Gastroesophageal Junction and Gastric Adenocarcinoma.

Authors:  Sam C Wang; Joanne F Chou; Vivian E Strong; Murray F Brennan; Marinela Capanu; Daniel G Coit
Journal:  Ann Surg       Date:  2016-02       Impact factor: 12.969

5.  Prognostic importance of baseline neutrophil to lymphocyte ratio in patients with advanced papillary thyroid carcinomas.

Authors:  Ju-Yeon Kim; Taejin Park; Sang-Ho Jeong; Chi-Young Jeong; Young-Tae Ju; Young-Joon Lee; Soon-Chan Hong; Woo-Song Ha; Sang-Kyung Choi; Eun Jung Jung
Journal:  Endocrine       Date:  2013-11-23       Impact factor: 3.633

6.  Extended multi-organ resection for cT4 gastric carcinoma: A retrospective analysis.

Authors:  Longbin Xiao; Mingzhe Li; Fengfeng Xu; Huishao Ye; Wenhui Wu; Shuo Long; Wenfeng Li; Yulong He
Journal:  Pak J Med Sci       Date:  2013-04       Impact factor: 1.088

7.  Prognostic significance of neutrophil lymphocyte ratio in patients with gastric cancer: a meta-analysis.

Authors:  Xi Zhang; Wei Zhang; Li-jin Feng
Journal:  PLoS One       Date:  2014-11-17       Impact factor: 3.240

8.  Usefulness of pretreatment neutrophil to lymphocyte ratio in predicting disease-specific survival in breast cancer patients.

Authors:  Hany Noh; Minseob Eomm; Airi Han
Journal:  J Breast Cancer       Date:  2013-03-31       Impact factor: 3.588

9.  Surgical outcomes and prognostic factors of T4 gastric cancer patients without distant metastasis.

Authors:  Ming-zhe Li; Liang Deng; Jing-jing Wang; Long-bin Xiao; Wen-hui Wu; Shi-bin Yang; Wen-feng Li
Journal:  PLoS One       Date:  2014-09-11       Impact factor: 3.240

10.  Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study.

Authors:  Yi Chen; Kai Chen; Xiaoyun Xiao; Yan Nie; Shaohua Qu; Chang Gong; Fengxi Su; Erwei Song
Journal:  BMC Cancer       Date:  2016-05-19       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.